ImmunOs Therapeutics Presents Details of Novel Bispecific Anti-Tumor Molecules at ESMO Immuno-Oncology Congress 2023 HLA/SIRPa bispecifics targeting LILRB1/2 plus CD47 checkpoint receptorDesigned to target myeloid, NK and T cells and to be precisely directed to tumor sitesPotent in vitro anti-tumor efficacy...